@biopointinc

Recently ranked 49th fastest growing private companies in the United States by Inc.5000 #BioPoint is a US based life sciences workforce solutions provider.

 Boston, MA
biopointinc.com
Joined July 2011
  • Tweets6.2K
  • Following1.6K
  • Followers3.4K
Enveda raised $311 million to advance its AI-discovered obesity and inflammatory disease drugs into later-stage development. biospace.com/business/ai-dru… #enveda #artificialintelligence #obesity #drugdevelopment #biotech

AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push

Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.

biospace.com
1
40
Novo Nordisk plans to increase oral obesity drug manufacturing capacity tenfold by 2030, aiming to supply treatments to 15 million patients. biospace.com/drug-delivery/n… #novonordisk #wegovy #glp1 #obesity #manufacturing

Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030

With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

biospace.com
34
Novartis’ recent clinical setbacks dragged down shares of several biotech peers with competing or related therapies. biospace.com/business/novart… #novartis #biotech #clinicaltrials #pharma #drugdevelopment

Novartis drags peers down with triple asset stumble

Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.

biospace.com
1
46
The FDA paused new enrollment in Biohaven’s opakalim epilepsy trials after toxicity findings in rodents, creating another setback for the drug’s development. biospace.com/fda/biohaven-ta… #biohaven #epilepsy #fda #clinicaltrials #biotech

Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug

The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its...

biospace.com
40
The FDA made Michael Davis and Karim Mikhail permanent heads of CDER and CBER, bringing greater leadership stability to the agency. biospace.com/fda/acting-cber… #fda #cder #cber #biotech #regulatory

Acting CBER, CDER heads become permanent as FDA works to restore stability

The decision to promote Michael Davis and Karim Mikhail from acting to permanent division heads comes as the FDA awaits the potential confirmation of Heidi Overton, President Donald Trump’s nominee...

biospace.com
465
Structure Therapeutics reported promising obesity data for its oral GLP-1 and amylin candidates, strengthening its position in the weight-loss market. biospace.com/drug-developmen… #structuretherapeutics #glp1 #obesity #weightloss #biotech

Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop

Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s...

biospace.com
44
Biotech is gaining momentum as M&A, venture funding and IPO activity rebound, setting a positive outlook for the rest of 2026. biospace.com/business/biotec… #biotech #lifesciences #mergersandacquisitions #venturecapital #pharma

Biotech is back, with H1 progress smoothing glide path through end of year: Truist

With M&A rising, venture capital returning and policy risks easing, biotech is on a positive trajectory following a prolonged post-pandemic slump, Truist Securities declared after a survey of sector...

biospace.com
20
Revolution Medicines’ Rasonque showed promising results in RAS-mutant lung cancer, supporting its ongoing Phase 3 trial. biospace.com/drug-developmen… #revolutionmedicines #lungcancer #oncology #clinicaltrials #biotech

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall...

biospace.com
45
Biotech funding announcements can help job seekers identify companies likely to hire before positions are publicly posted. biospace.com/career-advice/f… #biotech #lifesciences #hiring #careers #jobsearch

Follow the money: How funding announcements can help identify jobs before they’re posted

Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the funding...

biospace.com
20
GSK is advancing its mRNA flu vaccine to Phase 3 after showing stronger immune responses than existing vaccines in a mid-stage trial. biospace.com/drug-developmen… #gsk #mrna #influenza #clinicaltrials #vaccines

GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality

GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the...

biospace.com
43
Arrowhead’s Redemplo showed strong triglyceride reductions in Phase 3, but analysts remain divided over its competitive edge against Ionis’ Tryngolza. biospace.com/drug-developmen… #arrowhead #redemplo #clinicaltrials #cardiovascular #biotech

Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split

Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.

biospace.com
42
Lilly’s Mounjaro won FDA approval to reduce cardiovascular risk in adults with type 2 diabetes. biospace.com/fda/lilly-joins… #lilly #mounjaro #fda #cardiovascular #glp1

Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.

biospace.com
54
Revolution Medicines could emerge as a major oncology player following FDA approval of Rasonque for pancreatic cancer. biospace.com/business/revmed… #revolutionmedicines #oncology #pancreaticcancer #fda #biotech

RevMed could become ‘next oncology titan’ with Rasonque nod

A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.

biospace.com
1
68
Revolution Medicines received FDA approval for Rasonque, a groundbreaking pancreatic cancer drug, 6.5 months ahead of schedule. biospace.com/drug-developmen… #revolutionmedicines #pancreaticcancer #fda #oncology #biotech

RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.

biospace.com
45
Bausch + Lomb is advancing its dry eye therapy to Phase 3 despite missing its primary Phase 2 endpoint, citing promising earlier results. biospace.com/drug-developmen… #bauschlomb #dryeye #clinicaltrials #ophthalmology #biotech

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.

biospace.com
22
The FDA extended its review of Capricor’s Duchenne therapy by three months to evaluate additional data and a refined indication. biospace.com/fda/capricors-d… #capricor #duchenne #fda #celltherapy #biotech

Capricor’s Duchenne therapy has new life after FDA grants 3-month extension

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new...

biospace.com
62
Novo Nordisk is testing lower maintenance doses of oral Wegovy to improve flexibility and patient experience. biospace.com/drug-developmen… #novonordisk #wegovy #glp1 #obesity #clinicaltrials

Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

biospace.com
51
Regeneron won FDA approval for Pasatru, becoming the second U.S.-approved treatment for rare bone disease FOP. biospace.com/fda/regeneron-w… #regeneron #fda #raredisease #biotech #pharma

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.

biospace.com
42
Eleven biopharma companies are hiring across New Jersey, with more than 300 positions listed at the time of publication. biospace.com/job-trends/11-c… #biopharma #hiring #lifesciences #newjersey #careers

11 companies hiring in New Jersey

Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.

biospace.com
30
LEO Pharma acquired rights to a late-stage rare disease drug in a $435 million deal, expanding its dermatology portfolio. biospace.com/business/leo-ad… #leopharma #raredisease #dermatology #biotech #pharma

LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug

This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.

biospace.com
34
Load more